Improved diagnostic test for estrogen receptor status in breast cancer - multiple phosphorylation state

Description:

Estrogen receptor (Erα) status has become widely used as a key predictive biomarker of potential responsiveness to endocrine therapy in breast cancer. Positive receptor status predicts a positive outcome to endocrine therapy. This includes both estrogen analogue (including Tamoxifen) therapy and aromatase inhibitor therapy.

 

It was subsequently learned that the phosphorylation status of Erα provides an improved predictive tool for breast cancer responsiveness to endocrine therapy.

 

The Murphy technology provides an improved predictive tool is based on single- and multi-variate analysis of the specific pattern of phosphorylation at 7 epitopes. This provides:

 

·         A diagnostic tool to determine the best type of therapy for a given breast cancer patient.

 

·         A tool to assist in the evaluation of SERM or aromatase inhibitor drugs for breast cancer.

 

Figure 1. Multiple phosphorylation sites on Erα

 

 

Figure 2. Phosphorylation epitope immunohistochemical stain of breast cancer cell nuclei. Figure 3. Relative death or recurrence rates of in patients with positive and negative phosphorylation at one of the epitpes.

 

For more information download the Tech-op here

 

Tech ID

Inventors

Patent Status

License Status

80.02.758

Dr. Leigh Murphy, et al

Biochemistry &  Medical Genetics

University of Manitoba

Provisional patent :
61/251,690

Worldwide, exclusive

 

This patent portfolio is available for licensing to qualified development partners.

Patent Information:
Category(s):
Physical Sciences
For Information, Contact:
Odd Bres
Technology Manager
University of Manitoba
204-474-9407
odd_bres@umanitoba.ca
Inventors:
Gilbert Arthur
Robert Bittman
Keywords:
© 2025. All Rights Reserved. Powered by Inteum